Products for Research Use Only
RegisterLogin

Lisavanbulin

CAT: 0804-HY-19916-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19916-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862). Lisavanbulin is a BBB-penetrant and orally active antitumor agent, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin is also a spindle assembly checkpoint activator. Lisavanbulin induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma[1][2][3][4].
CAS Number
1263384-43-5
Product Name Alternative
BAL-101553
UNSPSC
12352005
Target
Checkpoint Kinase (Chk) ; Microtubule/Tubulin
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lisavanbulin.html
Purity
99.24
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(C(CN2C3=CC=CC=C3N=C2C4=NON=C4NCCC#N)=O)C=C1)[C@@H](N)CCCCN
Molecular Formula
C26H29N9O3
Molecular Weight
515.57
References & Citations
[1]Spriano F, et al. Assessment of lisavanbulin (BAL101553) as an anti-lymphoma agent[J]. bioRxiv, 2023: 2022.12. 31.521730.|[2]Joerger, M., et al., (2023) . Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Investigational new drugs, 41 (2), 267–275. |[3]Holdhoff, M., et al., (2024) . Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma. Neuro-oncology advances, 6 (1), vdae150. |[4]Genoud, V., et al., (2021) . Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin) . JCI insight, 6 (18), e142980.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
T88188-01Lisavanbulin
GTR19238348-01Lisavanbulin dihydrochloride

Popular Products